iBio (NASDAQ:IBIO – Get Free Report) and Myriad Genetics (NASDAQ:MYGN – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.
Insider and Institutional Ownership
7.9% of iBio shares are owned by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are owned by institutional investors. 1.5% of iBio shares are owned by company insiders. Comparatively, 1.9% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings for iBio and Myriad Genetics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iBio | 1 | 0 | 5 | 2 | 3.00 |
| Myriad Genetics | 2 | 5 | 1 | 0 | 1.88 |
iBio currently has a consensus target price of $5.83, suggesting a potential upside of 661.23%. Myriad Genetics has a consensus target price of $4.02, suggesting a potential upside of 0.92%. Given iBio’s stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Myriad Genetics.
Risk and Volatility
iBio has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500.
Profitability
This table compares iBio and Myriad Genetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iBio | N/A | -40.66% | -35.78% |
| Myriad Genetics | -13.96% | -16.09% | -8.10% |
Earnings & Valuation
This table compares iBio and Myriad Genetics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iBio | $100,000.00 | 492.81 | -$33.04 million | ($0.34) | -2.25 |
| Myriad Genetics | $806.60 million | 0.47 | -$365.90 million | ($1.19) | -3.34 |
iBio has higher earnings, but lower revenue than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.
Summary
iBio beats Myriad Genetics on 9 of the 15 factors compared between the two stocks.
About iBio
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
About Myriad Genetics
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
